1 mL BAC
6 units
resulting U-100 draw
- Concentration
- 5 mg/mL
- BAC added
- 1 mL
SingleInvestigationalEarly HumanModerate confidenceSourced
Kisspeptin
A reproductive neuropeptide studied in specialist fertility research. Molecule length, bolus versus infusion and ovarian context materially change the protocol.
Evidence context, not a personal protocol
Quantities below reproduce their stated source context—label, human study, laboratory work or educational guide. They do not assess suitability, product equivalence or individual risk.
Community-reported schedule
Community-reported · not a validated scheduleCommunity dose schedule
A community-provenance subcutaneous kisspeptin-10 pattern from authenticated forum archives, favouring intermittent dosing to limit tolerance. Community reports only, not a validated or trial-verified schedule.
Reported maximum quantityChoose the maximum quantity reported by this community line. Any earlier phase can be selected below for its arithmetic.
Reported per-use quantity
Select a point for its calculation examples- 3x/week (intermittent)300 mcgReports favour intermittent dosing because tolerance builds with daily use; the wider range spans about 65 mcg up to 1 mg three times weekly.
Vial-aware arithmetic
Reconstitution examples, up to 3 mL
Choose the vial quantity and BAC water first. The diagram and results below update for the selected 300 mcg reported quantity. Higher-strength vials may naturally land outside the 20-30 unit band.
BAC water selected
3 mL
Basic example limit: 3 mL maximum. Check the actual vial and product-specific limits.
U-100 draw18 U
20-30 U reference band
2 mL BAC
12 units
resulting U-100 draw
- Concentration
- 2.5 mg/mL
- BAC added
- 2 mL
3 mL BAC
18 units
resulting U-100 draw
- Concentration
- 1.667 mg/mL
- BAC added
- 3 mL
Shown in the diagram. Closest of these examples to 25 units.
Formula: draw units = selected mg × BAC mL ÷ vial mg × 100. The 20-30 unit band is a measurement reference, not a recommendation. Results are mathematical examples, not preparation instructions.
Dosage and protocol evidence
Each card states what the quantities are based on. A third-party or animal schedule is not a validated human dose.
Human StudySubcutaneous bolusSingle monitored exposure
Women undergoing in vitro fertilisation
A single subcutaneous kisspeptin-54 bolus at 1.6, 3.2, 6.4 or 12.8 nmol/kg after follicle monitoring
The study used ultrasound-defined timing to trigger oocyte maturation within a full IVF protocol.
View sourceHuman StudySubcutaneous infusion pumpEight-hour monitored infusion
Healthy women in the early follicular phase
Eight-hour subcutaneous kisspeptin-54 infusion at 0.1, 0.3 or 1.0 nmol/kg/hour
This four-person physiology study used an infusion pump and serial hormone sampling.
View sourceCommunity GuideSubcutaneous in reportsIntermittent; often two to three times weekly
authenticated research-forum (Peppys) kisspeptin-10 reports and reference charts
Subcutaneous kisspeptin-10 reports range from about 65-100 mcg daily up to 1 mg three times a week, with reference charts anchoring 100 mcg nightly; many favour intermittent dosing such as every other day or two to three times weekly because tolerance is reported to build with daily use
Forum provenance from an authenticated archive with usernames omitted, describing the labelled kisspeptin-10 molecule rather than the kisspeptin-54 used in the cited trials. Reports conflict on both dose and cadence and on whether testosterone rises at all; the archive treats this as a poorly researched compound.
View sourceEvidence summary
A reproductive neuropeptide studied in specialist fertility research. Molecule length, bolus versus infusion and ovarian context materially change the protocol.
Protocol basis
The cited protocols are specialist reproductive studies with different molecular forms and delivery patterns. Those details are essential to interpreting any quantity.
What remains uncertain
There is no general-purpose schedule, and retail product identity may not match the kisspeptin form used in a cited trial.
Community provenance (Peppys)
An authenticated research-forum archive describes subcutaneous use of the labelled kisspeptin-10 molecule, kept distinct from the kisspeptin-54 in the cited fertility trials. Reported quantities conflict, spanning roughly 65-100 mcg daily up to 1 mg three times a week, while reference charts list 100 mcg nightly. The recurring theme is tolerance building rapidly with daily dosing, so many reports favour intermittent schedules such as every other day or two to three times weekly; luteinising-hormone rises are described more consistently than testosterone gains, and several reports note irritability. Usernames and post numbers are omitted and the figures are logged as community provenance without endorsement. The planner above reproduces the arithmetic of these reported quantities; it does not validate them.
Online research community archive check
The archive contains passing libido, pulse and reconstitution mentions but no actual kisspeptin quantity, frequency or cycle. No community schedule was added from those mentions (raw/peptide-education/pe-bremelanotide-pt141.md:954-967).
Warnings and contraindications
Kisspeptin-10 and kisspeptin-54 are different research molecules.
Fertility studies require ultrasound, hormone monitoring and specialist timing.
A research schedule cannot be separated from ovarian stimulation and rescue procedures.
Shared across protocols
Supplies and general handling
Keep the universal checklist short. Product-specific labelling and source documentation always take priority over a general guide.
Research vial
Select the labelled vial quantity used in the calculation.
View Peppys vialBacteriostatic water
Use only a diluent appropriate to the research method and formulation.
View Peppys BAC waterU-100 measuring syringe
Use a new sterile device for every entry. Source locally.
Source locallyWipes and sharps container
Plan clean handling and immediate sharps disposal. Source locally.
Source locallyStorage follows the label
Do not apply a universal refrigerator rule. Follow the product, diluent and study documentation for temperature, light and expiry.
Use sterile equipment once
CDC injection-safety guidance calls for a new sterile needle and syringe for each injection and entry into a medication container.
Stability is formulation-specific
Do not infer a post-mixing lifetime from BAC water alone. Discard material when identity, integrity or sterility is in doubt.